

REMARKS

Claims 1 to 17 are pending in the application.

Restriction Requirement

In the Office Action, it was alleged that Claims 1 to 17 are generic to a plurality of disclosed patentably distinct species comprising pyrans, thiomorpholine, and morpholines. Applicant is required under 35 U.S.C. § 121 to elect a single disclosed species.

It is not clear to Applicant from reading the Office Action in view of claim 1 what are the alleged patentably distinct inventions. However, Applicant desires to be fully responsive to the restriction requirement. Accordingly, Applicant elects the first single disclosed species of claim 12: 3-(3,5-difluoro-4-hydroxy-benzyl)-8-methyl-2,4-dioxo-1,2,3,4,7,8-hexahydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid (2-methoxy-pyridin-4-ylmethyl)-amide. This species is a compound of claim 11 wherein Y⁵ is N(R⁵).

In view of the above remarks, Applicants request consideration of claims 1 to 17.

Respectfully submitted,

Date: April 26, 2005

Claude F. Purchase, Jr.
Claude F. Purchase, Jr.
Reg. No. 47,871
Pfizer Inc.
2800 Plymouth Road
Ann Arbor, MI 48105
Tel. (734) 622-1692
Fax (734) 622-1553